PL3298030T3 - Przeciwnowotworowy polipeptyd fuzyjny - Google Patents
Przeciwnowotworowy polipeptyd fuzyjnyInfo
- Publication number
- PL3298030T3 PL3298030T3 PL16729794.4T PL16729794T PL3298030T3 PL 3298030 T3 PL3298030 T3 PL 3298030T3 PL 16729794 T PL16729794 T PL 16729794T PL 3298030 T3 PL3298030 T3 PL 3298030T3
- Authority
- PL
- Poland
- Prior art keywords
- fusion polypeptide
- cancer fusion
- cancer
- polypeptide
- fusion
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167927 | 2015-05-18 | ||
| EP16150508 | 2016-01-08 | ||
| PCT/EP2016/061071 WO2016184882A1 (en) | 2015-05-18 | 2016-05-18 | Anti-cancer fusion polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3298030T3 true PL3298030T3 (pl) | 2023-05-08 |
Family
ID=56134305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16729794.4T PL3298030T3 (pl) | 2015-05-18 | 2016-05-18 | Przeciwnowotworowy polipeptyd fuzyjny |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10913778B2 (pl) |
| EP (2) | EP3298030B1 (pl) |
| JP (1) | JP6947642B2 (pl) |
| KR (1) | KR102685748B1 (pl) |
| CN (1) | CN108112253B (pl) |
| AU (1) | AU2016262845B2 (pl) |
| BR (1) | BR112017020445A2 (pl) |
| CA (1) | CA2980838A1 (pl) |
| DK (1) | DK3298030T5 (pl) |
| ES (1) | ES2938525T3 (pl) |
| FI (1) | FI3298030T3 (pl) |
| HR (1) | HRP20230145T1 (pl) |
| HU (1) | HUE061108T2 (pl) |
| LT (1) | LT3298030T (pl) |
| MX (1) | MX2017014716A (pl) |
| PL (1) | PL3298030T3 (pl) |
| RS (1) | RS64002B1 (pl) |
| RU (2) | RU2021119777A (pl) |
| SG (1) | SG11201707426SA (pl) |
| SI (1) | SI3298030T1 (pl) |
| WO (1) | WO2016184882A1 (pl) |
| ZA (1) | ZA201706061B (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10927154B2 (en) * | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| DK3292137T3 (da) * | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| BR112017026292A2 (pt) | 2015-07-15 | 2018-09-11 | Pieris Pharmaceuticals Gmbh | muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| RU2019123613A (ru) | 2017-01-03 | 2021-02-05 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9 |
| CN110121510B (zh) | 2017-01-06 | 2024-06-11 | 克雷森多生物制剂有限公司 | 程序性细胞死亡(pd-1)的单结构域抗体 |
| AU2018209178B2 (en) * | 2017-01-18 | 2021-07-29 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for LAG-3 |
| WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
| SG11202003978UA (en) * | 2017-11-13 | 2020-05-28 | Crescendo Biologics Ltd | Molecules that bind to cd137 and psma |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| JP2021519292A (ja) | 2018-03-26 | 2021-08-10 | ４エスツェー アクチェンゲゼルシャフト | 癌療法のためのｈｄａｃ阻害薬とｃｄ１３７作動薬とを含む併用 |
| WO2020025659A1 (en) * | 2018-07-31 | 2020-02-06 | Pieris Pharmaceuticals Gmbh | Novel fusion protein specific for cd137 and pd-l1 |
| JP7476219B2 (ja) * | 2019-02-26 | 2024-04-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質 |
| JP2022526367A (ja) * | 2019-03-29 | 2022-05-24 | ピエリス ファーマシューティカルズ ゲーエムベーハー | リポカリンムテインの吸入投与 |
| JP7301155B2 (ja) * | 2019-04-12 | 2023-06-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | リポカリンムテインを含む二重特異性抗原結合分子 |
| JP2022530216A (ja) * | 2019-04-23 | 2022-06-28 | エルジー・ケム・リミテッド | 免疫グロブリンのＦｃ領域およびＧＤＦ１５を含む融合ポリペプチド |
| BR112021026376A2 (pt) * | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
| TW202118770A (zh) * | 2019-07-30 | 2021-05-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN115960242B (zh) * | 2021-09-09 | 2023-10-17 | 广东东阳光药业股份有限公司 | 抗癌结合分子及其应用 |
| WO2024064713A1 (en) * | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2032831T5 (es) | 1986-08-19 | 2001-02-16 | Genentech Inc | Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| CN1073119C (zh) | 1994-05-18 | 2001-10-17 | 吸入治疗系统公司 | 干扰素干粉配方的方法及组合物 |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (fr) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Procede de preparation de dispersions a base de composants chromogenes |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| NZ508249A (en) | 1998-06-08 | 2003-02-28 | F | Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7235520B2 (en) | 2000-09-21 | 2007-06-26 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
| EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7118915B2 (en) | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| CN101516907B (zh) | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| WO2008015239A2 (en) | 2006-08-01 | 2008-02-07 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| PT2178921E (pt) | 2007-07-17 | 2016-03-23 | Squibb & Sons Llc | Anticorpos monoclonais contra glipicano-3 |
| EP2235053A1 (en) | 2007-10-19 | 2010-10-06 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| WO2009156456A1 (en) | 2008-06-24 | 2009-12-30 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| BR112012013662B1 (pt) | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico |
| CN103154023B (zh) | 2010-08-16 | 2017-04-05 | 皮里斯制药有限公司 | 铁调素的结合蛋白 |
| NZ714128A (en) | 2010-09-09 | 2017-10-27 | Pfizer | 4-1bb binding molecules |
| JP6100694B2 (ja) | 2010-11-15 | 2017-03-22 | ピエリス ファーマシューティカルズ ゲーエムベーハー | グリピカン−３（ｇｐｃ３）に対して親和性を有するヒトリポカリン２の突然変異タンパク質 |
| US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| EP2928913A1 (en) * | 2012-12-10 | 2015-10-14 | Fred Hutchinson Cancer Research Center | Lipocalin fusion partners |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| US10927154B2 (en) | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| MX2016012552A (es) * | 2014-04-07 | 2017-01-09 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| CN107207574A (zh) | 2015-01-28 | 2017-09-26 | 皮里斯制药有限公司 | 血管生成特异性的新型蛋白 |
| KR20170116158A (ko) | 2015-02-18 | 2017-10-18 | 사노피 | 피오베르딘 및 피오켈린에 특이적인 신규한 단백질 |
| BR112017020434A2 (pt) | 2015-05-04 | 2018-06-26 | Pieris Pharmaceuticals Gmbh | polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2 |
| DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| CN114456252A (zh) | 2015-05-18 | 2022-05-10 | 皮里斯制药有限公司 | 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-05-18 HU HUE16729794A patent/HUE061108T2/hu unknown
- 2016-05-18 JP JP2017560331A patent/JP6947642B2/ja active Active
- 2016-05-18 EP EP16729794.4A patent/EP3298030B1/en active Active
- 2016-05-18 LT LTEPPCT/EP2016/061071T patent/LT3298030T/lt unknown
- 2016-05-18 MX MX2017014716A patent/MX2017014716A/es unknown
- 2016-05-18 SI SI201631659T patent/SI3298030T1/sl unknown
- 2016-05-18 ES ES16729794T patent/ES2938525T3/es active Active
- 2016-05-18 CA CA2980838A patent/CA2980838A1/en active Pending
- 2016-05-18 BR BR112017020445A patent/BR112017020445A2/pt active Search and Examination
- 2016-05-18 RS RS20230084A patent/RS64002B1/sr unknown
- 2016-05-18 RU RU2021119777A patent/RU2021119777A/ru unknown
- 2016-05-18 DK DK16729794.4T patent/DK3298030T5/da active
- 2016-05-18 AU AU2016262845A patent/AU2016262845B2/en active Active
- 2016-05-18 HR HRP20230145TT patent/HRP20230145T1/hr unknown
- 2016-05-18 CN CN201680028941.3A patent/CN108112253B/zh active Active
- 2016-05-18 FI FIEP16729794.4T patent/FI3298030T3/fi active
- 2016-05-18 KR KR1020177035641A patent/KR102685748B1/ko active IP Right Grant
- 2016-05-18 WO PCT/EP2016/061071 patent/WO2016184882A1/en active Application Filing
- 2016-05-18 US US15/575,309 patent/US10913778B2/en active Active
- 2016-05-18 SG SG11201707426SA patent/SG11201707426SA/en unknown
- 2016-05-18 PL PL16729794.4T patent/PL3298030T3/pl unknown
- 2016-05-18 EP EP22216061.6A patent/EP4219535A1/en active Pending
- 2016-05-18 RU RU2017135539A patent/RU2754466C2/ru active
-
2017
- 2017-09-06 ZA ZA2017/06061A patent/ZA201706061B/en unknown
-
2021
- 2021-02-05 US US17/169,209 patent/US11919931B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249526A1 (zh) | 抗癌融合多肽 | |
| ZA201706061B (en) | Anti-cancer fusion polypeptide | |
| HK1244019A1 (zh) | 融合蛋白 | |
| ZA201802261B (en) | Polypeptides | |
| HK1250041A1 (zh) | 多肽 | |
| GB201509413D0 (en) | Fusion protein | |
| EP3188758C0 (en) | SIRP-ALPHA ANTIBODY FUSION PROTEINS | |
| HK1232136A1 (zh) | 融合蛋白 | |
| HK1246315A1 (zh) | 細胞因子融合蛋白 | |
| EP3362556C0 (en) | POLYPEPTIDE VARIANTS | |
| GB201504691D0 (en) | Fusion protein | |
| IL253004A0 (en) | il-17a binding polypeptides | |
| HK1250040A1 (zh) | 多肽 | |
| SI3087179T1 (sl) | Fuzijski polipeptidi z izboljšanimi lastnostmi, povezani z omega hidroksilazo | |
| SI3390620T1 (sl) | Fuzijske variante polipeptida z izboljšanimi lastnostmi, povezane z omega-hidroksilazo | |
| HK1257937A1 (zh) | 融合蛋白 | |
| SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
| GB201602850D0 (en) | Fusion proteins | |
| PT3298030T (pt) | Polipeptídeo de fusão anticancro | |
| GB201617799D0 (en) | Fusion polypeptide | |
| GB201503789D0 (en) | Fusion polypeptide | |
| GB201502166D0 (en) | Bonding polypeptides |